BioSpace News Archive

Aldeyra Therapeutics, Inc. announced positive top-line results from the Phase 3 INVIGORATE-2 Clinical Trial of 0.25% reproxalap ophthalmic solution, an investigational new drug, in patients with allergic conjunctivitis.

Altimmune, Inc. announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of its 24-week clinical trial of pemvidutide in the treatment of non-alcoholic fatty liver disease in an oral presentation at the EASL International Liver Congress™ 2023 in Vienna, Austria.

Mersana Therapeutics, Inc. announced that the U.S. Food and Drug Administration has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company’s ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer.

Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping dexlansoprazole 30 mg capsules, a generic version of Takeda’s Dexilant®.

Zucara Therapeutics Inc. announced additional funding from JDRF, the leading global Type 1 diabetes research and advocacy organization.

Avalyn Pharma Inc. announced that CFO Marc Schneebaum will present at the H.C. Wainwright 2nd Annual Private Company Showcase, which is taking place June 20-22, 2023 on Kiawah Island, SC.

Femasys Inc. announced that it has appointed Mr. Keith J. Kendall and Mr. Alistair Milnes to its board of directors.

Helocyte, Inc., a subsidiary company of Fortress Biotech, Inc., announced that the National Cancer Institute has awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.

Indaptus Therapeutics, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced that CEO Jeffrey A. Meckler will participate in the Maxim Group Virtual Healthcare Conference presented by Maxim Group and hosted by M-Vest.

Nemaura Medical, Inc. announces it will exhibit and provide product demonstrations of its non-invasive daily-wear glucose sensor platform at the 83rd Scientific Sessions of the American Diabetes Association.